1-3 of 3
Mark P. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Treatment Regimen with Moroctocog Alfa (AF-CC) on Bleeding Frequency in Pediatric Aged Subjects with Moderately Severe to Severe Hemophilia A

Mark P. Smith, MD FRACP, FRCPA, Jeremy Rupon, MD, Yasser Wali, MD, Hala Remawi, MD, Joan Korth-Bradley, PharmD, PhD, Lynne Smith, MBA, Pablo Rendo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1205.
https://doi.org/10.1182/blood-2018-99-111891
Published: 2018
Journal Articles

A Post-Marketing Surveillance Study of the Safety and Efficiacy of Refacto® (Moroctocog Alfa, B-Domain Deleted Recombinant Factor VIII) (St. Louis-Derived Active Substance in the Treatment and Prevension of Bleeding Episodes in Hemophilia a Patients.

Jay M. Feingold, MD, PhD, Mark P. Smith, MD, Richard Littlewood, MD, Paul Giangrande, MD, ReFacto STL Study Group
Journal: Blood
Blood (2004) 104 (11): 4023.
https://doi.org/10.1182/blood.V104.11.4023.4023
Published: 2004
Journal Articles

Evidence for a role for Gα i1 in mediating weak agonist-induced platelet aggregation in human platelets: reduced Gα i1 expression and defective G i signaling in the platelets of a patient with a chronic bleeding disorder

Clinical Trials & Observations
Yatin M. Patel, Kirti Patel, Salman Rahman, Mark P. Smith, Gillian Spooner, Rushika Sumathipala, Michael Mitchell, Geraldine Flynn, Alexandra Aitken, Geoffrey Savidge
Journal: Blood
Blood (2003) 101 (12): 4828–4835.
https://doi.org/10.1182/blood-2002-10-3080
Published: 2003